227322-00-1

Upstream product

• 5239-82-7 cyclopropylacetic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 6542-60-5 2-cyclopropylacetonitrile 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1352754-36-9 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-allyl)-[1,3]oxazinan-2-one 
• 1352754-34-7 4-[(S)-1-(4-bromo-phenyl)-ethylamino]-1-cyclopropyl-butan-2-one 
• 1352754-35-8 1-[(S)-1-(4-bromo-phenyl)-ethylamino]-3-cyclopropylmethyl-5-methyl-hex-5-en-3-ol 
• 1352754-37-0 3-[(S)-1-(4-bromo-phenyl)-ethyl]-6-cyclopropylmethyl-6-(2-methyl-oxiranylmethyl)-[1,3]oxazinan-2-one 
• 1352754-39-2 3-[(S)-1-(4-bromo-phenyl)-ethyl]-(S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-[1,3]oxazinan-2-one 
• 1352754-38-1 (S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-[1,3]oxazinan-2-one 
• 1352753-96-8 1-[5-(4-{(S)-1-[(S)-6-cyclopropylmethyl-6-(2-hydroxy-2-methyl-propyl)-2-oxo-[1,3]oxazinan-3-yl]-ethyl}-phenyl)-pyridin-2-yl]-cyclopropanecarboxylic acid amide 
• 1383716-35-5 1-(4'-(cyclopropylmethyl)-2-(4-(methylsulfonyl)phenylamino)-4,5'-bipyrimidin-2'-ylamino)-2-methylpropan-2-ol 
• 1383716-34-4 4-(4'-(cyclopropylmethyl)-2'-(2-hydroxy-2-methylpropylamino)-4,5'-bipyrimidin-2-ylamino)benzonitrile 
• 1383716-33-3 VPS34-IN1 
• 1383715-90-9 N₂-cyclohexyl-4'-cyclopropylmethyl-N₂'-methyl-[4,5']bipyrimidinyl-2,2'-diamine 
• 1383716-46-8 1-((4'-(cyclopropylmethyl)-2-(pyridin-4-ylamino)-[4,5'-bipyrimidin]-2'-yl)amino)-2-methylpropan-2-ol 
• 646522-76-1 trifluoromethanesulfonic acid 2-(2-cyclopropylacetyl)phenyl ester 
• 646522-95-4 2-cyclopropyl-1-(2-hydroxy-phenyl)-ethanone 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA

Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering to the subject a compound of Formula (I): [INSERT FORMULA] (I), or a pharmaceutically acceptable salt thereof.

FERROPORTIN INHIBITORS AND METHODS OF USE

The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.

CRF1 RECEPTOR ANTAGONIST, PHARMACEUTICAL FORMULATIONS AND SOLID FORMS THEREOF FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA

Provided are methods related to treating congenital adrenal hyperplasia in a subject in need thereof comprising administering 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[( 1 S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-l,3-thiazol-2-amine (Formula 1), or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical formulations and solid forms of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(lS)-2-cyclopropyl-l-(3-fluoro-4-methylphenyl)ethyl]-5-mcthyl-N -prop-2 -ynyl-l,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, and their use in the treatment of congenital adrenal hyperplasia (CAH).

4-(2,4-BIS(2-HYDROXYPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID DERIVATIVES AS NOVEL IRON CHELATORS

The invention relates to novel compounds of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as iron chelators, more particularly for the use in the prophylaxis and/or treatm

Palladium(II)-Catalyzed C(sp 3)-H Activation of N,O-Ketals towards a Method for the β-Functionalization of Ketones

A method for the formal β-functionalization of aliphatic ketones via a palladium-catalyzed sp 3 C-H activation pathway is reported. An N,O-ketal directs an aliphatic C-H carbonylation to form γ-lactams which upon hydrolysis generate γ-keto carb

7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS

A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS

The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF

The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or lnterleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.